SPRX-105 Drug Patent Profile
Which patents cover Sprx-105, and when can generic versions of Sprx-105 launch?
Sprx-105 is a drug marketed by Numark and is included in one NDA.
The generic ingredient in SPRX-105 is phendimetrazine tartrate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sprx-105
A generic version of SPRX-105 was approved as phendimetrazine tartrate by CHARTWELL on October 30th, 1991.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SPRX-105?
- What are the global sales for SPRX-105?
- What is Average Wholesale Price for SPRX-105?
Summary for SPRX-105
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 547 |
| DailyMed Link: | SPRX-105 at DailyMed |
US Patents and Regulatory Information for SPRX-105
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Numark | SPRX-105 | phendimetrazine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 088024-001 | Dec 22, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
